NCT01067144

Brief Summary

The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
422

participants targeted

Target at P75+ for phase_3 pain

Timeline
Completed

Started May 2010

Longer than P75 for phase_3 pain

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 9, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 11, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2010

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
2 years until next milestone

Results Posted

Study results publicly available

June 28, 2018

Completed
Last Updated

May 5, 2022

Status Verified

May 1, 2022

Enrollment Period

6.2 years

First QC Date

February 9, 2010

Results QC Date

June 1, 2018

Last Update Submit

May 3, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to Pain Resolution

    Time to pain resolution was defined as 5 consecutive reports of "0" average pain at the surgical site (as reported by the patient on a scale of 0-10, with lower scores corresponding to less pain ("0" = no pain) and higher scores corresponding to more pain). Planned call frequency was daily for 3 months, weekly thereafter up to 6 months, and monthly thereafter up to 2 years after surgery.

    Up to 2 years

Secondary Outcomes (5)

  • Time to Opioid Cessation

    Up to 2 years

  • Count of Participants With Continued Pain at 6 Months

    Month 6

  • Count of Participants With Continued Pain at 1 Year

    Year 1

  • Count of Participants With Continued Opioid Use at 6 Months

    Month 6

  • Count of Participants With Continued Opioid Use at 1 Year

    Year 1

Study Arms (2)

Control

PLACEBO COMPARATOR

Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively

Drug: Lorazepam (active control)Drug: Placebo (inactive)

Gabapentin

EXPERIMENTAL

1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.

Drug: Gabapentin

Interventions

1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.

Also known as: Fanatrex, Gabarone, Gralise, Neurontin, Nupentin
Gabapentin

0.5 mg Lorazepam (active control) given pre-operatively in a single dose.

Control

2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.

Control

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 to 75
  • Undergoing a scheduled surgery
  • English speaking
  • Ability and willingness to complete questionnaires or use Palm Pilot

You may not qualify if:

  • Known kidney disease
  • Currently receiving gabapentin or (pregabalin) lyrica already
  • Cognitive impairment
  • Previous history of excessive sedation or adverse reaction to gabapentin (not it was tried but ineffective for nerve pain)
  • Coexisting chronic pain \> 4/10 disorder in area other than surgical target
  • Plan to move out of state
  • Condition that would in judgment of team member make patient likely to be lost to follow-up
  • Elevated suicidality
  • Known pregnancy
  • Current symptoms of ataxia, dizziness, or sedation
  • Narrow angle glaucoma
  • Severe respiratory insufficiency (ie, severe emphysema or chronic obstructive pulmonary disease)
  • History of gastric bypass surgery and obstructive sleep apnea requiring continuous positive airway pressure (CPAP)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Stanford, California, 94305, United States

Location

Related Publications (2)

  • Hah J, Mackey SC, Schmidt P, McCue R, Humphreys K, Trafton J, Efron B, Clay D, Sharifzadeh Y, Ruchelli G, Goodman S, Huddleston J, Maloney WJ, Dirbas FM, Shrager J, Costouros JG, Curtin C, Carroll I. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial. JAMA Surg. 2018 Apr 1;153(4):303-311. doi: 10.1001/jamasurg.2017.4915.

  • Hah JM, Cramer E, Hilmoe H, Schmidt P, McCue R, Trafton J, Clay D, Sharifzadeh Y, Ruchelli G, Goodman S, Huddleston J, Maloney WJ, Dirbas FM, Shrager J, Costouros JG, Curtin C, Mackey SC, Carroll I. Factors Associated With Acute Pain Estimation, Postoperative Pain Resolution, Opioid Cessation, and Recovery: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2019 Mar 1;2(3):e190168. doi: 10.1001/jamanetworkopen.2019.0168.

MeSH Terms

Conditions

PainBreast NeoplasmsLung Neoplasms

Interventions

GabapentinLorazepam

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

AminesOrganic Chemicalsgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAmino AcidsAmino Acids, Peptides, and ProteinsBenzodiazepinonesBenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title
Dr. Ian Carroll
Organization
Stanford University

Study Officials

  • Ian R Carroll

    Stanford University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Anesthesiology, Perioperative and Pain Medicine

Study Record Dates

First Submitted

February 9, 2010

First Posted

February 11, 2010

Study Start

May 1, 2010

Primary Completion

July 1, 2016

Study Completion

July 1, 2016

Last Updated

May 5, 2022

Results First Posted

June 28, 2018

Record last verified: 2022-05

Locations